Sector News

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

May 21, 2022
Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by.

The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.” However, what exactly is being exchanged remains unknown; Kelun has more than a dozen oncology assets, with 11 in clinical trials and three in preclinical testing.

A Merck spokesperson said in an email the company had nothing to add beyond what was released in the disclosure.

Translated from Chinese, the disclosure says Merck will pay $17 million off the top and an additional $30 million after the agreement is formally signed. Kelun stands to earn up to $1.36 billion in cumulative milestones.

It’s not the first time Kelun has made a licensing splash. In 2018, it inked a deal for its midstage PD-L1 antibody with Harbour BioMed for up to $350 million.

As for Merck, the plucking of Kelun’s project comes as it reportedly considers larger M&A plays to capitalize on biotech’s bear market. A few of the names supposedly on the company’s shortlist are Mirati Therapeutics, Strand Therapeutics and Arcturus Therapeutics.

By Max Bayer

Source: fiercebiotech.com

comments closed

Related News

July 3, 2022

Novo Nordisk joins with nursing group to highlight correlation between Type 2 diabetes and cardio risk

Life sciences

Despite atherosclerotic cardiovascular disease (ASCVD) being the leading cause of death for people with Type 2 diabetes, half of those people have no idea of this risk. Novo Nordisk has teamed up with the Preventive Cardiovascular Nurses Association (PCNA) for “Making the Connection,” a program to help increase understanding of the link between the two diseases.

July 3, 2022

First treatment for ‘broken heart syndrome’ trialled

Life sciences

The first ever treatment for broken heart syndrome – also known as Takotsubo cardiomyopathy – is to be trialled by researchers at the University of Aberdeen. Scientists will trial a programme of exercise conditioning and psychological therapy for people who have been diagnosed with the condition following a £300,000 grant from the British Heart Foundation.

July 3, 2022

Nestlé acquiring The Better Health Company in market expansion deal

Life sciences

Nestlé Health Science is set to acquire The Better Health Company (TBHC), as part of its goals to grow global market share while spurring innovation across the nutrition industry. The acquisition includes the GO Healthy brand with its vitamins and supplements, Egmont, the Manuka honey brand and New Zealand Health Manufacturing, an Auckland-based manufacturing facility for vitamins minerals and supplements.